Patent ID: 9440922
Filing Date: 2016-09-13
CPC Classification: A61K,A61P,C07D,C07F,C07H

Claim Text:
1. A pharmaceutical for the treatment of cancer, cancer metastasis, or depression, comprising one or more pharmaceutically acceptable carriers and as an active ingredient a compound represented by Formula (I): wherein, <1> a C <2> a C <3> a C <4> a C <5> a 4- to 10-membered heterocycloalkyl group which may be substituted by one or more R <6> a C <7> a C <8> a C <9> a 5- to 14-membered heteroarylsulfonyl group, <10> an oxo group, <11> a cyano group, <12> a C <13> a C <14> a (C <15> a C <16> a (C <17> a hydroxy group, <18> a (C <19> a C <1> a hydroxy group, <2> halogen atom, <3> a hydroxycarbonyl group, <4> a C <5> a 4- to 10-membered nitrogen-containing heterocycloalkylcarbonyl group which may be substituted by one or more R <6> a (C <7> a 4- to 10-membered heterocycloalkyl group which may be substituted by one or more R <8> a 5- to 14-membered heteroaryl group, <9> a (C <10> a C <11> a C <12> a C <13> a C <1> a C <2> a C <3> a C <4> a (C <5> a 4- to 10-membered heterocycloalkyl group, <1> a hydroxy group, <2> a C <3> a C <4> a C <5> a (C <6> a C <7> a 4- to 10-membered nitrogen-containing heterocycloalkylsulfonyl group which may be substituted by C <8> a (C <1> a C <2> a C <3> a hydroxy group, <4> a C <5> a C <6> a C <7> a C <8> a (C <9> a C <10> an oxo group, or <11> a 4- to 10-membered heterocycloalkyl group which may be substituted by substituent(s) selected from the group consisting of [1] a C <1> a C <2> a hydroxy group, <3> a cyano group, <4> a (C <5> a C <6> a C <7> a 4- to 10-membered heterocycloalkyl group which may be substituted by C <8> a 5- to 14-membered heteroaryl group, <1> a hydroxy group, or <2> a C <1> a C <2> a C <3> a C <4> a C <5> a C <6> a 4- to 10-membered heterocycloalkyl group which may be substituted by one or more R <7> a C <8> a hydroxy group, or [9] a C